Loading...
01/10 19:14
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company's financial performance shows declining revenue and increased losses, with challenges in the hair restoration business and economic uncertainties. Despite some positive developments, such as the sale of the Venus Hair business and strategic focus on growth, the lack of guidance and increased debt obligations weigh negatively. The absence of Q&A insights further limits positive sentiment. Overall, the negative financials and uncertainties overshadow potential growth catalysts, leading to a negative outlook.
Total Revenue $13.8 million, down $1.2 million or 8% year-over-year. The decrease was driven by a $1.1 million or 12% decrease in U.S. revenue and a $0.2 million or 3% decrease in international revenue. The decline was attributed to softness in the Hair Restoration business, customer financing pressures, economic uncertainty, and tight credit markets.
Energy-Based Devices (EBD) Revenue $9.5 million, up 2% year-over-year. This growth was driven by strong execution, improved sales efficiency, and prioritization of core products in the U.S., including Bliss MAX and Versa PRO.
Gross Profit $8.8 million, down $1.1 million or 11% year-over-year. The decline was primarily due to lower revenue in the Venus Hair business, customer uncertainty, and tighter third-party lending practices. Gross margin decreased to 64% from 66.1% due to U.S. tariffs and higher device system costs.
Operating Expenses $18.3 million, up $1.2 million or 7% year-over-year. Approximately one-third of the increase was due to legal and professional fees related to the sale of the Venus Hair business. Excluding these, operating expenses increased 4%.
Operating Loss $9.5 million, compared to $7.2 million in the third quarter of 2024. The increase was due to higher operating expenses and lower gross profit.
Net Loss $22.6 million, compared to $9.3 million in the third quarter of 2024. The increase was primarily driven by an $11.3 million noncash loss on debt extinguishment and a $0.2 million noncash loss on disposal of a subsidiary.
Adjusted EBITDA Loss $7.8 million, compared to $5.9 million in the third quarter of 2024. The increase reflects higher operating expenses and lower gross profit.
Cash and Cash Equivalents $5.9 million as of September 30, 2025, compared to $4.3 million as of December 31, 2024. The improvement was due to equity capital market transactions and debt-to-equity exchanges.
Total Debt Obligations $30.1 million as of September 30, 2025, compared to $39.7 million as of December 31, 2024. The reduction was achieved through debt-to-equity exchanges and support from Madryn Asset Management.
Venus NOVA launch: Venus NOVA, a next-generation multi-application platform, received 510(k) clearance. It integrates advanced technologies for body contouring, muscle conditioning, skin treatments, and wrinkle and cellulite reduction. The product is expected to address unmet needs in the body and skin market, particularly for patients using GLP-1 medications. A limited commercial launch is planned for December, targeting long-term growth in the multibillion-dollar market.
Market focus shift: The company is focusing on the U.S. market by prioritizing core products like Bliss MAX and Versa PRO. This is part of a strategy to stabilize energy-based device (EBD) sales, which grew 2% year-over-year in Q3.
Financial restructuring: The company improved its balance sheet by converting $11.5 million in debt to equity and increasing financing capacity under its bridge loan facility. Cash and cash equivalents increased to $5.9 million, while total debt obligations decreased to $30.1 million.
Cost management: Operating expenses increased by 7% year-over-year, partly due to legal fees for the Venus Hair business sale. Excluding these, expenses rose modestly by 4%, reflecting disciplined cost management.
Sale of Venus Hair business: The company is working to finalize the sale of its Venus Hair business to MHG Co. Ltd. Challenges with the counterparty have delayed the transaction, but the company remains committed to closing the deal to focus on its global medical aesthetics business.
Hair Restoration Business Challenges: Customer financing pressures, economic uncertainty, and tight credit markets are hindering robotic system adoption in the Venus Hair business. Additionally, uncertainty surrounding the time to close the definitive agreement to sell the Venus Hair business to MHG Co. Ltd has further impacted sales.
Economic and Credit Market Conditions: Economic uncertainty and tight credit markets are negatively affecting customer financing and capital equipment sales, particularly in the Venus Hair business.
Pending Sale of Venus Hair Business: Challenges with the counterparty in closing the sale of the Venus Hair business to MHG Co. Ltd have led to delays, requiring legal assistance to resolve the situation. This delay has created uncertainty and impacted the company's financial performance.
Gross Margin Decline: Gross margin decreased due to U.S. tariffs on imported devices and higher manufacturing overhead costs spread over a lower volume base.
Operating Expenses Increase: Operating expenses increased due to legal and professional fees related to the Venus Hair business sale and inflationary pressures, despite efforts in cost containment.
Net Loss and Adjusted EBITDA Loss: The company reported a significant net loss of $22.6 million and an adjusted EBITDA loss of $7.8 million for Q3 2025, reflecting ongoing financial challenges.
Debt Obligations: The company has total debt obligations of approximately $30.1 million as of September 30, 2025, despite progress in debt reduction.
Venus NOVA Launch and Market Penetration: The company anticipates the U.S. commercial introduction of Venus NOVA in December 2025 to contribute to long-term growth by penetrating the multibillion-dollar body and skin market. The product is expected to redefine noninvasive treatments and address unmet needs, particularly for patients using GLP-1 medications.
GLP-1 Usage Growth: The company expects GLP-1 usage to grow to over 32 million patients globally by 2030, presenting an opportunity to highlight complementary benefits of Venus's body technology, particularly in skin tightening.
Fourth Quarter Sequential Growth: The company is targeting sequential growth in the fourth quarter of 2025, driven in part by the limited commercial launch of Venus NOVA.
Proceeds from Venus Hair Business Sale: The company expects the proceeds from the pending sale of the Venus Hair business to enhance its balance sheet and financial condition, providing capital to fund strategic growth initiatives.
Strategic Alternatives and Shareholder Value: The company intends to continue evaluating strategic alternatives to maximize shareholder value, including targeted investments to support long-term growth.
The selected topic was not discussed during the call.
The company's financial performance shows declining revenue and increased losses, with challenges in the hair restoration business and economic uncertainties. Despite some positive developments, such as the sale of the Venus Hair business and strategic focus on growth, the lack of guidance and increased debt obligations weigh negatively. The absence of Q&A insights further limits positive sentiment. Overall, the negative financials and uncertainties overshadow potential growth catalysts, leading to a negative outlook.
The earnings call summary indicates several negative factors: declining international sales, supply chain disruptions, a significant drop in gross margin, increased operating expenses, and widening losses. Although there is some positive news, such as the sale of the Venus Hair business and a slight increase in U.S. revenue, the overall financial health and strategic uncertainties outweigh these. The lack of full-year guidance and high debt obligations further contribute to a negative outlook, likely leading to a stock price decline of -2% to -8% over the next two weeks.
The earnings call reveals significant challenges: a 22% revenue decline, increased operating loss, and lack of full-year guidance. Despite debt reduction and strategic shifts, the market conditions and financial strain are concerning. The Q&A highlighted uncertainties, particularly around tariffs and sales delays. While there is potential with the new product, the lack of specifics and distributor hesitancy add to the negative sentiment. Without a clear shareholder return plan and with financial metrics pointing to struggles, the stock is likely to experience a negative reaction.
The earnings call reflects a negative sentiment due to several factors: a significant revenue decline (22% YoY), increased operating losses, and a lack of financial guidance for 2025. The Q&A revealed concerns about tariffs and unclear management strategies, adding to uncertainties. Although debt was reduced and a new product launch is anticipated, these positives are overshadowed by weak financial performance and market challenges. Without share repurchases or dividends, shareholder returns are stagnant. These factors suggest a likely negative stock price reaction in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
